CSBR — Champions Oncology Income Statement
0.000.00%
Last trade - 00:00- $114.63m
- $111.68m
- $50.16m
- 72
- 50
- 89
- 81
Annual income statement for Champions Oncology, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 32.1 | 41 | 49.1 | 53.9 | 50.2 |
| Cost of Revenue | |||||
| Gross Profit | 15.2 | 19.6 | 25.5 | 24.3 | 20.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 33.9 | 40.7 | 48.5 | 59.1 | 57.5 |
| Operating Profit | -1.8 | 0.366 | 0.607 | -5.26 | -7.36 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.84 | 0.437 | 0.583 | -5.27 | -7.31 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.98 | 0.362 | 0.548 | -5.33 | -7.28 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.98 | 0.362 | 0.548 | -5.33 | -7.28 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.98 | 0.362 | 0.548 | -5.33 | -7.28 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.148 | 0.021 | 0.034 | -0.355 | -0.516 |